157 related articles for article (PubMed ID: 9164421)
1. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers.
Ukkonen H; Saraste M; Akkila J; Knuuti MJ; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
Clin Pharmacol Ther; 1997 May; 61(5):596-607. PubMed ID: 9164421
[TBL] [Abstract][Full Text] [Related]
2. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
[TBL] [Abstract][Full Text] [Related]
3. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
Segreti JA; Marsh KC; Polakowski JS; Fryer RM
J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
[TBL] [Abstract][Full Text] [Related]
4. Changes in myocardial oxygen consumption and efficiency with heart failure therapy measured by 11C acetate PET.
Beanlands RS; Schwaiger M
Can J Cardiol; 1995 Apr; 11(4):293-300. PubMed ID: 7728641
[TBL] [Abstract][Full Text] [Related]
5. Direct cardiac effects of dobutamine, dopamine, epinephrine, and levosimendan in isolated septic rat hearts.
Zausig YA; Geilfus D; Missler G; Sinner B; Graf BM; Zink W
Shock; 2010 Sep; 34(3):269-74. PubMed ID: 19997056
[TBL] [Abstract][Full Text] [Related]
6. Effects of levosimendan on myocardial contractility and oxygen consumption.
Todaka K; Wang J; Yi GH; Stennett R; Knecht M; Packer M; Burkhoff D
J Pharmacol Exp Ther; 1996 Oct; 279(1):120-7. PubMed ID: 8858984
[TBL] [Abstract][Full Text] [Related]
7. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart.
Meyer K; Schipke JD; Klocke RC; Gams E; Korbmacher B
Thorac Cardiovasc Surg; 2008 Oct; 56(7):379-85. PubMed ID: 18810693
[TBL] [Abstract][Full Text] [Related]
8. Myocardial efficiency during levosimendan infusion in congestive heart failure.
Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
[TBL] [Abstract][Full Text] [Related]
9. Oxygen-wasting effect of inotropy: is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan.
Müller S; How OJ; Jakobsen Ø; Hermansen SE; Røsner A; Stenberg TA; Myrmel T
Circ Heart Fail; 2010 Mar; 3(2):277-85. PubMed ID: 20018954
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
Banfor PN; Preusser LC; Campbell TJ; Marsh KC; Polakowski JS; Reinhart GA; Cox BF; Fryer RM
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H238-48. PubMed ID: 17982006
[TBL] [Abstract][Full Text] [Related]
11. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.
Michaels AD; McKeown B; Kostal M; Vakharia KT; Jordan MV; Gerber IL; Foster E; Chatterjee K
Circulation; 2005 Mar; 111(12):1504-9. PubMed ID: 15781741
[TBL] [Abstract][Full Text] [Related]
14. Influence of temperature on the positive inotropic effect of levosimendan, dobutamine and milrinone.
Rieg AD; Schroth SC; Grottke O; Hein M; Ackermann D; Rossaint R; Schälte G
Eur J Anaesthesiol; 2009 Nov; 26(11):946-53. PubMed ID: 19687740
[TBL] [Abstract][Full Text] [Related]
15. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
Givertz MM; Andreou C; Conrad CH; Colucci WS
Circulation; 2007 Mar; 115(10):1218-24. PubMed ID: 17339544
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.
Bowman P; Haikala H; Paul RJ
J Pharmacol Exp Ther; 1999 Jan; 288(1):316-25. PubMed ID: 9862786
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
18. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs.
Leather HA; Ver Eycken K; Segers P; Herijgers P; Vandermeersch E; Wouters PF
Crit Care Med; 2003 Sep; 31(9):2339-43. PubMed ID: 14501965
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of levosimendan in the early stages of endotoxemia.
Cunha-Goncalves D; Perez-de-Sa V; Dahm P; Grins E; Thörne J; Blomquist S
Shock; 2007 Jul; 28(1):71-7. PubMed ID: 17510599
[TBL] [Abstract][Full Text] [Related]
20. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
